Johnson & Johnson will likely shrug off failure of a late-stage study using Actelion's Opsumit (macitentan) in patients with pulmonary arterial hypertension due to Eisenmenger Syndrome and keep pursuing M&A talks aimed at buying Europe’s largest biotech company, analysts said.
Actelion Pharmaceuticals Ltd.Jan. 23 said the MAESTRO Phase III trial of Opsumit failed to demonstrate a benefit for the...








